Wheezing Clinical Trial
— TAILOROfficial title:
Biomarkers in Preschool Children With Wheeze to TArget Therapy wIth inhaLed cORticosteroids (TAILOR): a Feasibility Study".
Verified date | January 2024 |
Source | Imperial College London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Wheezing is common in preschool children and affects quality of life. Although asthma treatments such as inhaled steroids (ICS), which reduce swelling (inflammation) in the airways are used in this age group, they are often ineffective. That is because only some preschool children have the type of inflammation (known as Type 2 inflammation) that responds to ICS, thus many children are being unnecessarily exposed to side effects. It is difficult diagnosing Type 2 inflammation through history and examination, thus other indicators are needed to ensure ICS are only given to children who will benefit. These indicators are commonly known as biomarkers, and we are trying to find out if they are useful. We want to measure three biomarkers, without changing children's treatment. The first is blood eosinophils. which can be measured using a finger prick sample (like the blood drop used for measuring sugar levels in diabetic children). The second is to determine if allergic sensitization is present to allergens that are breathed in; these will be house dust mite, grass pollen, tree pollen, cat and dog hair. The final biomarker is a molecule that is produced in the airways of preschool children with Type 2 inflammation, called nitric oxide (NO). This is easily obtained, by having children breathe through a mask and collecting their breath in a bag, measuring NO later on. The children will be followed up with monthly electronic questionnaires and 3-monthly visits (virtual or face-to-face) for a year to evaluate whether these markers individually or in combination relate to subsequent wheezing outcomes, and how acceptable the measurements are to families using a questionnaire and focus group approach. The results will form the basis of the design of a national trial of biomarker-driven therapy in such children.
Status | Active, not recruiting |
Enrollment | 103 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 5 Years |
Eligibility | Inclusion Criteria: 1. Patients aged one to five years old presenting to primary care or emergency department or urgent care centre or identified from primary care records and have been diagnosed with wheezing by their GP or paediatrician who has decided to prescribe any bronchodilator, ICS or montelukast on clinical grounds 2. Parents/Carers able to understand and familiarize themselves with the study and are willing to provide informed consent Exclusion Criteria: 1. Inability to understand and cooperate with study procedures 2. Significant co-morbidity (respiratory or otherwise), for example cystic fibrosis (excluding atopic disorders such as eczema, allergic rhinitis and food allergy) 3. Withholding or withdrawal of informed consent 4. Severe procedural anxiety (needle phobia) 5. Child is already enrolled in another study involving investigational medicinal product (CTIMP) 6. History of anaphylaxis or near-fatal asthma that resulted in intubation / assisted ventilation. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | John Radcliffe Hospital | Oxford |
Lead Sponsor | Collaborator |
---|---|
Imperial College London | Asthma UK Centre for Applied Research |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acute attacks of wheeze defined as requiring an unscheduled health care visit | Exacerbation of the wheezing condition that will require a visit to a hospital that was not scheduled. This will be determined with monthly electronic questionnaires sent by email to the parents of preschool children with wheeze, as well as by follow-up face-to-face visits in primary care every 3 months. | 1 year follow-up period | |
Secondary | Carer days off work | Days the parent/carer has taken off work in order to be with their child that has an acute wheezing. This will be determined with monthly electronic questionnaires sent by email to the parents of preschool children with wheeze, as well as by follow-up face-to-face visits in primary care every 3 months. | 1 year follow-up period | |
Secondary | Children unable to attend childcare facility | Assessing the number of days a child did not attend a childcare facility due to exacerbation of his/her wheezing condition. This will be determined with monthly electronic questionnaires sent by email to the parents of preschool children with wheeze, as well as by follow-up face-to-face visits in primary care every 3 months. | 1 year follow-up period | |
Secondary | Use of oral corticosteroids | In case a child has been prescribed oral corticosteroids, this has to be declared so that we can assess treatment effectiveness according to the biomarkers tested. This will be determined with monthly electronic questionnaires sent by email to the parents of preschool children with wheeze, as well as by follow-up face-to-face visits in primary care every 3 months. | 1 year follow-up period | |
Secondary | Use of inhaled ß-2 agonist (rescue therapy) | In case a child has been prescribed ß-2 agonists, this has to be declared so that we can assess treatment effectiveness according to the biomarkers tested. This will be determined with monthly electronic questionnaires sent by email to the parents of preschool children with wheeze, as well as by follow-up face-to-face visits in primary care every 3 months. | 1 year follow-up period | |
Secondary | Assessment id respiratory or wheezing condition is under control | • Assessment if children's respiratory or wheezing condition is under control by using the TRACKTM score questionnaire (Test for Respiratory and Asthma Control in Kids) | 1 year follow-up period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04669288 -
AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department
|
Phase 3 | |
Withdrawn |
NCT04584034 -
Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial
|
Phase 4 | |
Terminated |
NCT02269761 -
Chest Ultrasound of ER Patients With Cough or SOB
|
||
Enrolling by invitation |
NCT00775697 -
Montelukast in Children With Wheezing
|
Phase 4 | |
Completed |
NCT00749528 -
Evaluation of Toxic Metals, Trace Elements and Total Antioxidant Activity in Children With Recurrent Wheezing
|
N/A | |
Recruiting |
NCT00494624 -
Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children
|
Phase 4 | |
Recruiting |
NCT04128592 -
Non-invasive Differential Diagnosis of Noisy Breathing Infants and Toddlers
|
N/A | |
Recruiting |
NCT06093152 -
Video Assisted Study of Salbutamol Response in Viral Wheezing
|
||
Completed |
NCT01452945 -
Bedside Lung Ultrasound in Young Children Presenting to the Emergency Department (ED) With Wheezing
|
N/A | |
Withdrawn |
NCT00628303 -
A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants
|
Phase 3 | |
Completed |
NCT01028560 -
Allergy Immunotherapy for the Reduction of Asthma
|
Phase 1/Phase 2 | |
Completed |
NCT00626808 -
A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children
|
Phase 4 | |
Completed |
NCT00507676 -
Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing
|
N/A | |
Completed |
NCT03600428 -
Safety of LAIV4 in Children With Asthma
|
Phase 4 | |
Recruiting |
NCT06106646 -
Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up
|
||
Recruiting |
NCT05710081 -
Bacterial Lysate In Preventing Asthma
|
Phase 3 | |
Completed |
NCT04011709 -
A Methodology Trial Using the VR647 Inhalation System in Pediatric Subjects Who Have Previously Received Inhaled Therapy
|
Early Phase 1 | |
Active, not recruiting |
NCT03377192 -
Impedance Pneumography in Assessment of Asthma Control in Preschool Children
|
||
Completed |
NCT01142505 -
Wheeze and Intermittent Treatment
|
Phase 3 | |
Recruiting |
NCT05684848 -
Evaluate the Effect of Nasal Spray in the Prevention of RTI in Children With Pre-school Wheezing
|
N/A |